The significance of low PU.1 expression in patients with acute promyelocytic leukemia.

Journal of Hematology & Oncology
Xuehua ZhuKankan Wang

Abstract

Although the importance of the hematopoietic transcription factor PU.1 in acute myeloid leukemia (AML) has been demonstrated, the expression of PU.1 in acute promyelocytic leukemia (APL) patient samples awaits further investigation. The current study used APL patient samples to assess the expression pattern of PU.1 in the initiation and progression of APL. We used real-time RT-PCR to compare PU.1 expression between de novo APL patient samples and normal blood specimens, and the results indicated that PU.1 expression was significantly lower in newly diagnosed APL patient samples as compared to normal hematopoietic cells. Further evidence showed a significant inverse correlation between the expression level of PML-RARα and that of PU.1. In addition, we analyzed the correlation between PML-RARα and PU.1 expression in a large population of AML patients retrieved from the expression profiles. The results showed that PU.1 expression was lower in patients with APL than other AML subtypes and there was also a trend towards increasing PU.1 expression from AML-M0 to AML-M5, with the exception of AML-M3 (APL). These observations suggested that PU.1 expression was reduced by PML-RARα in APL patients. Furthermore, we measured PU.1 expressio...Continue Reading

References

Apr 1, 1996·The Journal of Experimental Medicine·M A GoodellR C Mulligan
Mar 21, 1998·Science·Z G WangP P Pandolfi
Sep 19, 2001·Current Opinion in Hematology·J L PollockT J Ley
Nov 13, 2001·Oncogene·P Kastner, S Chan
Jun 13, 2002·Proceedings of the National Academy of Sciences of the United States of America·Louise M KellyD Gary Gilliland
Sep 16, 2003·Blood Cells, Molecules & Diseases·Richard Dahl, M Celeste Simon
Apr 16, 2004·The New England Journal of Medicine·Peter J M ValkRuud Delwel
Jul 1, 2004·Blood·Mary E RossJames R Downing
Jan 20, 2005·The Journal of Experimental Medicine·Stephen L NuttLi Wu
Aug 23, 2005·Proceedings of the National Academy of Sciences of the United States of America·Matthew J WalterTimothy J Ley
Jan 25, 2006·Proceedings of the National Academy of Sciences of the United States of America·Donald MetcalfStephen Nutt
Mar 22, 2007·Proceedings of the National Academy of Sciences of the United States of America·Kalindi ParmarJulian D Down

❮ Previous
Next ❯

Citations

Mar 21, 2013·Proceedings of the National Academy of Sciences of the United States of America·Hui ZhangKan-Kan Wang
Sep 17, 2013·Journal of Cellular Physiology·Rabia IslamHyun-Mo Ryoo
Apr 18, 2015·Journal of Hematology & Oncology·Parisa RasighaemiAlister C Ward
Sep 11, 2014·Biological Chemistry·Boet van Riel, Frank Rosenbauer
May 21, 2015·Journal of Leukocyte Biology·Julian WampflerMario P Tschan
May 6, 2016·Journal of Hematology & Oncology·Shuyong WeiKankan Wang

❮ Previous
Next ❯

Datasets Mentioned

BETA
GSE10358
GSE1159

Methods Mentioned

BETA
PCR
FACS
flow cytometry

Software Mentioned

Affymetrix MAS

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.